EGFL7是一种促血管生成因子。它已被广泛地描述为具有重要的作用，在肾小管发生和血管生成的调节，主要在胚胎发生和器官发生期间。它主要与NOTCH通路有关，但有报道显示与MAPK和整合素通路有关。鉴于其与血管生成和这些其他途径的关联，有几项研究将EGFL7与致癌作用相关联。事实上,大多数研究都指出EGFL7是一种癌基因，其中一些提示EGFL7表达可能是预后或用于患者随访的生物标志物。这里,我们回顾了EGFL7相关的分子途径，并强调了一些描述EGFL7在肿瘤发生中作用的研究，按肿瘤类型分开。除了它对血管生成的作用，EGFL7可能作为癌基因在其他途径中起作用，这使得它成为可能的生物标志物和靶向治疗的候选者。
EGFL7 is a proangiogenic factor. It has been widely described with having a vital role in tubulogenesis and regulation of angiogenesis, mainly during embryogenesis and organogenesis. It has been mainly associated with NOTCH pathway, but there are reports showing association with MAPK and integrin pathways. Given its association with angiogenesis and these other pathways, there are several studies associating EGFL7 with carcinogenesis. In fact, most of the studies have pointed to
EGFL7 as an oncogene, and some of them suggest
EGFL7 expression as a possible biomarker of prognosis or use for a patient\'s follow-up. Here, we
review the molecular pathways which
EGFL7 is associated and highlight several studies describing the role of
EGFL7 in tumorigenesis, separated by tumor type. Besides its role on angiogenesis,
EGFL7 may act in other pathways as oncogene, which makes it a possible biomarker and a candidate to targeted therapy.
